Business headlines from the Apex backend, organized by sectors and major public companies for faster market scanning.
On Mad Money, the host pointed to Johnson & Johnson’s drug profitability and balance-sheet strength, arguing that diversification can help investors weather sell-offs, though he did not spell out new-drug details in the reported segment.
THE APEX TIMES
THE APEX TIMES
The expansion brings Amazon Supply Chain Services’ LTL shipping option to companies that need only a portion of a truckload, using Amazon’s logistics assets and tracking tools.
THE APEX TIMES
The logistics unit Amazon Supply Chain Services is opening LTL shipping, allowing smaller shippers to use Amazon’s network rather than booking a full truckload.
THE APEX TIMES
With the FIFA World Cup starting June 11 in North America, Nike is leaning into major football marketing. The market, however, is still watching whether demand momentum can offset longer-running concerns about Nike’s reset and guidance.
THE APEX TIMES
The engine and defense contractor pointed to renewed demand outlines tied to China’s plan to buy 200 Boeing jets, while also highlighting a new U.S. Navy-related win in propulsion.
THE APEX TIMES
The Federal Aviation Administration has approved Boeing to begin Type Inspection Authorization Phase 4B for the 777X, a milestone tied to the aircraft’s long-running certification process. The update arrived as Boeing’s stock traded below targets cited by market commentary.
THE APEX TIMES
A market analysis flags a sharp reduction in institutional Nvidia shareholdings, suggesting at least some investors are taking profits or reassessing near-term expectations.
THE APEX TIMES
Facebook-parent Meta said it has agreed to lease capacity for an AI-enabled data center being built by Reliance Industries in Jamnagar, Gujarat, marking its first such facility in India. The project is slated for completion within about two years, with room to expand as Meta’s demand for AI computing grows.
THE APEX TIMES
The agreement gives Lilly rights to AlzeCure’s ACD680, a small-molecule gamma-secretase modulator designed to shift amyloid-beta production, as the company deepens its Alzheimer’s pipeline beyond its approved anti-amyloid therapy Kisunla.
